Kyverna Therapeutics (KYTX) Total Liabilities (2023 - 2026)

Kyverna Therapeutics' Total Liabilities history runs 4 years deep, the most recent figure standing at $61.4 million for Q1 2026.

• Quarterly Total Liabilities rose 67.67% year-over-year to $61.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.4 million (up 67.67% YoY) and the FY2025 annual result came in at $61.6 million, up 61.73% from the prior year.
• Total Liabilities was $61.4 million for Q1 2026 at Kyverna Therapeutics, roughly flat from $61.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $61.6 million in Q4 2025 and bottomed at $26.0 million in Q4 2023.
• A 4-year average of $39.6 million and a median of $36.6 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2025 — Total Liabilities dropped 3.5% — and 2026, when it surged 67.67%.
• Kyverna Therapeutics' Total Liabilities stood at $26.0 million in 2023, then jumped by 46.28% to $38.1 million in 2024, then jumped by 61.73% to $61.6 million in 2025, then dropped by 0.17% to $61.4 million in 2026.
• Business Quant data shows KYTX's Total Liabilities at $61.4 million in Q1 2026, $61.6 million in Q4 2025, and $35.2 million in Q3 2025.